IHT Wealth Management LLC Acquires 16,297 Shares of Johnson & Johnson (NYSE:JNJ)

IHT Wealth Management LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 37.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 59,683 shares of the company’s stock after acquiring an additional 16,297 shares during the quarter. IHT Wealth Management LLC’s holdings in Johnson & Johnson were worth $9,670,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Innealta Capital LLC acquired a new position in Johnson & Johnson in the second quarter valued at about $27,000. Highline Wealth Partners LLC bought a new position in shares of Johnson & Johnson in the third quarter valued at approximately $31,000. RPg Family Wealth Advisory LLC bought a new stake in Johnson & Johnson during the 3rd quarter worth approximately $35,000. Mowery & Schoenfeld Wealth Management LLC increased its holdings in Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after purchasing an additional 91 shares in the last quarter. Finally, Activest Wealth Management bought a new stake in shares of Johnson & Johnson during the third quarter worth $40,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on JNJ shares. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Guggenheim lifted their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Wells Fargo & Company upped their target price on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Finally, Citigroup boosted their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $175.67.

Johnson & Johnson Stock Performance

NYSE:JNJ traded down $1.29 during mid-day trading on Tuesday, hitting $153.51. The stock had a trading volume of 1,236,718 shares, compared to its average volume of 7,025,154. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company’s 50 day simple moving average is $159.15 and its 200 day simple moving average is $156.46. The stock has a market cap of $369.59 billion, a price-to-earnings ratio of 22.40, a PEG ratio of 2.75 and a beta of 0.51. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same quarter last year, the company posted $2.66 EPS. Johnson & Johnson’s quarterly revenue was up 5.2% compared to the same quarter last year. On average, equities research analysts forecast that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.23%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.